Prokinetic agents in the surgical patient

American Journal of Surgery

Volumn 177, Issue 6, 1999, Pages 508-514

  Thompson, Jon S ^a   Quigley, Eamonn M M ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETHANECHOL; CHOLINERGIC RECEPTOR STIMULATING AGENT; CISAPRIDE; DOMPERIDONE; DOPAMINE RECEPTOR BLOCKING AGENT; ERYTHROMYCIN; GRANISETRON; LEUPRORELIN; LOXIGLUMIDE; METOCLOPRAMIDE; MISOPROSTOL; NEOSTIGMINE; NONSTEROID ANTIINFLAMMATORY AGENT; OCTREOTIDE; ONDANSETRON; PROKINETIC AGENT; PROSTAGLANDIN; SEROTONIN AGONIST;

COLON DISEASE; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL DISEASE; GASTROINTESTINAL MOTILITY; ILEUS; OGILVIE SYNDROME; PRIORITY JOURNAL; REVIEW;

GASTROINTESTINAL AGENTS; GASTROINTESTINAL DISEASES; GASTROINTESTINAL MOTILITY; HUMANS; SURGICAL PROCEDURES, OPERATIVE;

EID: 0032772978     PISSN: 00029610     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9610(99)00104-X     Document Type: Review

References (96)

1. Quigley E.M.M. The clinical pharmacology of motility disorders the perils (and pearls) of prokinesia . Gastroenterology. 106:1994;1112-1114.
2. Humphreys T.J., Castell D.O. Effect of oral bethanechol on parameters of esophageal peristalsis. Dig Dis Sci. 26:1981;129-132.
3. Malagelada J.-R., Rees W.D.W., Mazzotta L.J., Go V.L.W. Gastric motor abnormalities in diabetic and post vagotomy gastroparesis effect of metoclopramide and bethanechol . Gastroenterology. 78:1980;286-293.
4. McCallum R.W., Fink S.M., Lerner E., Berkowitz D.M. Effects of metoclopramde and bethanechol on delayed gastric emptying in gastroesophageal reflux patients. Gastroenterology. 84:1983;1573-1577.
5. Myrhoj T., Olsen O., Wengel B. Neostigmine in postoperative intestinal paralysis a double blind, clinical controlled trial . Dis Colon Rectum. 31:1989;368-379.
6. Ramirez B., Richter J.E. Review article promotility drugs in the treatment of gastroesophageal reflux disease . Aliment Pharmacol Ther. 7:1993;5-20.
7. Albibi R., McCallum R.W. Metoclopramide pharmacology and clinical application . Ann Intern Med. 98:1983;86-95.
8. McCallum R.W. Clinical pharmacology forum motility agents and the gastrointestinal tract . Am J Med Sci. 312:1996;19-26.
9. Champion M.C., Hartnett M., Yen M. Domperidone, a new dopamine antagonist. Can Med Assoc J. 135:1986;457-461.
10. Soykan I., Sarosick I., McCallum R.W. The effect of chronic oral domperidone therapy in gastrointestinal symptoms, gastric emptying and quality of life in patients with gastroparesis. Am J Gastroenterol. 92:1997;976-980.
11. Silvers D., Kipnes M., Broadstone V., et al. Domperidone in the management of symptoms of diabetic gastroparesis efficacy, tolerability, and quality of life outcomes in a multicenter controlled trial . Clin Ther. 20:1998;438-453.
12. McCallum R.W. Cisapride a new class of prokinetic agent . Am J Gastroenterol. 86:1991;135-149.
13. Koop H., Mounikes H., Koop I., et al. Effect of the prokinetic drug cisapride on gastrointestinal hormone release. Scand J Gastroenterol. 21:1986;907-913.
14. Bedford T.A., Rowsatram D.J. Cisapride drug interactions of clinical significance . Drug Safety. 15:1996;167-175.
15. Abell T.L., Camilleri M., DiMagno E.P., et al. Long-term efficacy of oral cisapride in symptomatic upper gut dysmotility. Dig Dis Sci. 36:1991;621-626.
16. Ceccatelli P., Janssens J., VanTrappen G., et al. Cisapride restores the decreased lower esophageal sphincter pressure in reflux patients. Gut. 29:1988;631-635.
17. Gilbert R.J., Dodds W.J., Kahrilas P.J., et al. Effect of cisapride, a new prokinetic agent in esophageal motor dysfunction. Dig Dis Sci. 32:1987;1331-1336.
18. Wehrmann T., Lembcke B., Caspary W.F. Influence of cisapride on antroduodenal motor function in healthy subjects and diabetics with autonomic neuropathy. Aliment Pharmacol Ther. 5:1991;599-608.
19. Edwards C.A., Hole S., Brown C., Read N.W. Effect of cisapride on the gastrointestinal transit of a solid meal in normal human subjects. Gut. 28:1987;13-16.
20. Camilleri M., Malagelada J.-R., Abell T.L., et al. Effect of six weeks of treatment with cisapride in gastroparesis and intestinal pseudo-obstruction. Gastroenterology. 96:1989;705-712.
21. McHugh S., Lico S., Diamant N.E. Cisapride versus metoclopramide an acute study in diabetic gastroparesis . Dig Dis Sci. 37:1992;997-1001.
22. Richards R.D., Valenzuela J.A., Davenport K.S., et al. Objective and subjective results of a randomized, double-blind, placebo-controlled trial using cisapride to treat gastroparesis. Dig Dis Sci. 38:1993;811-816.
23. Benson M.J., Roberts J.P., Wingate D.L., et al. Small bowel motility following major intraabdominal surgery the effects of opiates and rectal cisapride . Gastroenterology. 106:1994;924-936.
24. Hallerback H., Bergman B., Bing H., et al. Cisapride in the treatment of postoperative ileus. Aliment Pharmacol Ther. 5:1991;503-511.
25. Verlinden M., Michiels G., Boghaert A., et al. Treatment of postoperative gastrointestinal atony. Br J Surg. 74:1987;614-617.
26. Malmud L.S., Maurer A.H., Sommers M.L., et al. The effect of oral cisapride on colonic transit. Aliment Pharmacol Ther. 1:1987;293-304.
27. Marbach P., Bauer W., Briner U., et al. Structure-function relationships of somatostatic analogs. Horm Res. 29:1988;54-58.
28. Neri M., Cuccurullo F., Marzio L. Effect of somatostatin on gallbladder volume and small intestinal motor activity in humans. Gastroenterology. 98:1990;316-321.
29. Soudah H.C., Hasler W.L., Owyang C. Effect of octreotide on intestinal motility and bacterial overgrowth in scleroderma. NEJM. 325:1991;1461-1467.
30. O'Donnell L.J.D., Watson A.J.M., Cameron D., Farthing M.J.G. Effect of octreotide on mouth-to-cecum transit time in healthy subjects in the irritable bowel syndrome. Aliment Pharmacol Ther. 4:1990;177-182.
31. Ewins D.L., Javaid A., Coskeran P.B., et al. Assessment of gallbladder dynamics, cholecystokinin release and the development of gallstones during octreotide treatment for acromegaly. Quart J Med. 83:1992;295-306.
32. Ahrendt S.A., McGuire G.E., Pitt H.A., Lillemoe K.D. Why does somatostatin cause gallstones. Am J Surg. 161:1991;177-183.
33. Gunshefski L.A., Rifley W.J., Slattery D.W., et al. Somatostatin stimulation of the normal esophagus. Am J Surg. 163:1992;59-62.
34. Richards W.O., Greeer R., O'Dorisio T.M., et al. Octreotide acetate induces fasting small bowel motility in patients with dumping syndrome. J Surg Res. 49:1990;483-487.
35. Haruma K., Wiste J.A., Camilleri M. Effect of octreotide on gastrointestinal pressure profiles in health and in functional organic gastrointestinal disorders. Gut. 35:1994;1064-1069.
36. Hasler W.L., Soudah H.C., Owyang C. A somatostatin analogue inhibits afferent pathways mediating perception of rectal distension. Gastroenterology. 104:1993;1390-1397.
37. Cullen J.J., Eagon C., Dozois E.J., Kelly K.A. Treatment of acute postoperative ileus with octreotide. Am J Surg. 165:1993;113-120.
38. Weber F.H., Richards R.D., McCallum R.W. Erythromycin a motilin agonist and gastrointestinal prokinetic agent . Am J Gastroenterol. 88:1993;485-490.
39. Tack J., Janssens J., Vantrappen G., et al. Effect of erythromycin on gastric motility in controls and in diabetic gastroparesis. Gastroenterology. 103:1992;72-79.
40. Fraser R., Shearer T., Fuller J., et al. Intravenous erythromycin overcomes small intestinal feedback on antral, pyloric and duodenal motility. Gastroenterology. 103:1992;116-119.
41. Janssens J., Peeters T.L., Vantrappen G., et al. Improvement of gastric emptying in diabetic gastroparesis by erythromycin. NEJM. 322:1990;1028-1031.
42. Mantides A., Xynos E., Chrysos E., et al. The effect of erythromycin in gastric emptying of solids and hypertonic liquids in healthy subjects. Am J Gastroenterol. 88:1993;198-202.
43. Richards R.D., Davenport K., McCallum R.W. The treatment of idiopathic and diabetic gastroparesis with acute intravenous and chronic oral erythromycin. Am J Gastroenterol. 88:1993;203-207.
44. Fiorucci S., Distrutti E., Bassotti G., et al. Effect of erythromycin administration on upper gastrointestinal motility in scleroderma patients. Scand J Gastroenterol. 29:1994;807-813.
45. Camilleri M. The current role of erythromycin in the clinical management of gastric emptying disorders. Am J Gastroenterol. 88:1993;169-171.
46. Mathias J.R., Clench M.H., Reeves-Darby V.G., et al. Effect of leuprolide acetate in patients with moderate to severe functional bowel disease. Dig Dis Sci. 39:1994;1155-1162.
47. Mathias J.R., Clench M.H., Abell T.L., et al. Effect of leuprolide acetate in treatment of abdominal pain and nausea in premenopausal women with functional bowel disease. Dig Dis Sci. 43:1998;1347-1355.
48. Akkerman L.M.A., Vos A., Hoekstra A., et al. Effect of ICS 205-930 (a specific 5HT3 receptor antagonist) on gastric emptying of a solid meal in normal subjects. Gut. 29:1988;1249-1252.
49. Nielsen O.H., Hvid-Jacobsen K., Lund P., et al. Gastric emptying and subjective symptoms of nausea lack of effect of a 5HT3 antagonist ondansetron on gastric emptying in patients with gastric stasis syndrome . Digestion. 46:1990;89-96.
50. Meyer D.M., Werth V.A., Beglinger C., et al. Role of cholecystokinin in regulation of gastrointestinal motor functions. Lancet. ii:1989;12-15.
51. Eberhart C.E., Dubois R.N. Eicosanoids and the gastrointestinal tract. Gastroenterology. 109:1995;285-301.
52. Soffer E.E., Launspack J. Effect of misoprostol on postprandial intestinal motility and orocecal transit time in humans. Dig Dis Sci. 18:1993;851-855.
53. Bassotti G., Bucaneve G., Furno P., et al. Double blind, placebo controlled study on the effects of diclofenac sodium and indomethacin on postprandial gastric motility in man. Dig Dis Sci. 42:1998;1172-1176.
54. Kelley M.C., Hocking M.P., Marchand S.D., Sninsky C.A. Ketorolac prevents postoperative small intestinal ileus in rats. Am J Surg. 165:1993;107-112.
55. Richter J.E. Long term management of gastroesophageal reflux disease and its complications. Am J Gastroenterol. 92:1997;305-359.
56. Wetscher G.J., Glaser K., Wieschemeyer T., et al. Cisapride enhances the effect of partial posterior fundoplication in esophageal peristalsis in GERD patients with poor esophageal contractility. Dis Dig Sci. 43:1998;1986-1990.
57. Shibara Y., Nimura Y., Toyoda S., et al. Acid reflux test for gastroesophageal reflux after distal gastectomy diagnosis and clinical effect of cisapride . J Am Coll Surg. 186:1998;595-600.
58. Pennather A., Tran A., Cioppi M., et al. Erythromycin strengthens the defective lower esophageal sphincter in patients with gastroesophageal reflux disease. Am J Surg. 167:1994;169-173.
59. Fich A., Neri M., Cammilleri M., et al. Stasis syndromes following gastric surgery clinical and motility features of sixty symptomatic patients . J Clin Gastroenterol. 12:1990;505-512.
60. Mathias J.R., Fernandez A., Sninsky C.A., et al. Nauseas, vomiting and abdominal pain after Roux-en-Y anastomosis motility of the jejunal limb . Gastroenterology. 88:1985;101-107.
61. Hinder R.A., Esser M.B., DeMeester T.R. Management of gastric emptying disorders following the Roux-en-Y procedure. Surgery. 104:1988;765-772.
62. Varis K. Diabetic gastroparesis. Scand J Gastroenterol. 24:1989;897-903.
63. Malagelada J.R. Diabetic gastroparesis in perspective. Gastroenterology. 107:1994;581-583.
64. Petrakis J., Vassilakis J.S., Karkaritsas N., et al. Enhancement of gastric emptying of solids by erythromycin in patients with Roux-en-Y gastrojejunostomy. Arch Surg. 133:1998;709-714.
65. Ramirez B., Eaker E.Y., Drane W.E., et al. Erythromycin enhances gastric emptying in patients with gastroparesis after vagotomy and antrectomy. Dig Dis Sci. 39:1994;2295-2300.
66. Chen J.D.Z., Lin Y.Z., Edmunds M.C., McCallum R.W. Effects of octreotide and erythromycin on gastric myoelectrical and motor activities in patients with gastroparesis. Dig Dis Sci. 43:1998;80-89.
67. McClelland R.N., Horton J.W. Relief of acute, persistent postvagotomy atony by metoclopramide. Ann Surg. 88:1978;439-447.
68. Tatsuta M., Ishi H., Nakaizumi A., et al. Effect of treatment with cisapride alone or in combination with domperidone on gastric emptying and gastrointestinal symptoms in dyspeptic patients. Aliment Pharmacol Ther. 6:1992;221-228.
69. Nadrowski L. Paralytic ileus recent advances in pathophysiology and treatment . Curr Surg. 40:1983;260-273.
70. Esser M.J., Mahoney J.L., Robinson J.C., et al. Effects of adrenergic agents on colonic motility. Surgery. 102:1987;416-423.
71. Condon R.E., Cowles V., Ekbom G.A., et al. Effects of halothane, enflurane, and nitrous oxide in colon motility. Surgery. 101:1987;81-85.
72. Graber J.N., Schulte W.J., Condon R.E., Cowles V.E. Relationship of duration of postoperative ileus to extent and site of operative dissection. Surgery. 92:1982;87-92.
73. Condon R.E., Frantzides C., Cowles V.E., et al. Resolution of postoperative ileus in humans. Ann Surg. 203:1986;574-581.
74. Resnick J., Greenwald D.A., Brandt L.J. Delayed gastric emptying and postoperative ileus after nongastric abdominal surgery. Part II. Am J Gastroenterol. 92:1997;934-940.
75. Cheape J.D., Wexner S.D., James K., Jagelman D.G. Does metoclopramide reduce the length of ileus after colorectal surgery? Dis Colon Rect. 34:1991;437-441.
76. Davidson E.D., Hersh T., Brinner R.A., et al. The effects of metoclopramide on postoperative ileus. Ann Surg. 190:1979;27-30.
77. Tollesson P.O., Cassuto J., Rimback G., et al. Treatment of postoperative ileus with cisapride. Scand J Gastroenterol. 26:1991;477-482.
78. Armstrong D.N., Ballantyne G.H., Modlin I.M. Erythromycin stimulates ileal motility by activation of dihydropyridine-sensitive calcium channels. J Surg Res. 52:1992;140-146.
79. Peeters T., Mathijis G., Depoorterc I., et al. Erythromycin is a motilin receptor antagonist. Am J Physiol. 157:1989;G470-G474.
80. Bonacini M., Quiason S., Reynolds M., et al. Effect of intravenous erythromycin on postoperative ileus. Am J Gastroenterol. 88:1993;208-211.
81. Cheng G., Cassissi C., Dressler G., et al. Salsalate, morphine and postoperative ileus. Am J Surg. 171:1996;85-89.
82. Camilleri M. Disorders of gastrointestinal motility in neurologic diseases. Mayo Clin Proc. 65:1990;825-846.
83. Krishnamurthy S., Schuffler M.D. Pathology of neuromuscular disorders of the small intestine and colon. Gastroenterology. 93:1987;610-639.
84. Colemont L.J., Camilleri M. Chronic intestinal pseudo-obstruction diagnosis and treatment . Mayo Clin Proc. 64:1989;60-70.
85. Bachulis B.L., Smith P.E. Pseudoobstruction of the colon. Am J Surg. 136:1978;66-72.
86. Euphrat E.J. Adynamic ileus of the colon. Arch Surg. 110:1975;224-225.
87. Lauderer J.R., Demers L.M., Bonnem E.M. Elevated prostaglandin E in idiopathic intestinal pseudoobstruction. NEJM. 295:1976;21.
88. Thayer M.L., Bubrick M.P., Jacobs D.M., Frykman S. Effects of ibuprofen on postoperative bowel motility and propulsion. Dis Colon Rectum. 31:1988;363-367.
89. Vanek V.W., Al-Salti M. Acute pseudoobstruction of the colon an analysis of 400 cases . Dis Colon Rectum. 29:1986;203-210.
90. Stephenson B.M., Morgan R., Salaman J.R., Wheeler M.H. Ogilvie's syndrome a new approach to an old problem . Dis Colon Rectum. 38:1995;424-427.
91. Turegamo-Fuentes F., Munoz-Jimenez F., Valle-Hernandes E.D., et al. Early resolution of Ogilvie's syndrome with intravenous neostigmine. Dis Colon Rectum. 40:1997;1353-1357.
92. Maccoll C., MacCannell K.L., Bayliss B., Lee S.S. Treatment of acute colonic pseudo obstruction with cisapride. Gastroenterology. 98:1990;773-776.
93. Hutchinson R., Griffiths C. Acute colonic pseudoobstruction a pharmacological approach . Ann Roy Coll Surg Engl. 74:1992;364-367.
94. Soffer E.E., Launspach J. Misoprostol is an effective treatment for patients with severe chronic constipation. Dig Dis Sci. 39:1994;929-933.
95. Muller-Lissner S.A. Treatment of chronic constipation with cisapride and placebo. Gut. 287:1987;1033.
96. Krevsky B., Maurer A.H., Malmud L.S., et al. Cisapride accelerates colonic transit in patients with colonic inertia. Am J Gastroenterol. 84:1989;822-827.